Discontinued — last reported Q1 '23
Biogen ADUHELM — Excess and obsolescence charges related to inventory remained flat by 0.0% to $275.00M in Q1 2023 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $275.00M to $275.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests poor demand forecasting or product obsolescence, while a decrease indicates efficient inventory management.
This metric represents the write-down of inventory value for a specific product due to expiration, lack of market demand...
Common in pharmaceutical companies managing drug launches with uncertain market uptake.
biib_segment_aduhelm_excess_and_obsolescence_charges_related_to_inventory| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | |
|---|---|---|---|---|---|---|
| Value | $120.00M | $275.00M | $275.00M | $275.00M | $275.00M | $275.00M |
| QoQ Change | — | +129.2% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +129.2% | +0.0% |